For years, Sara worked in a hospital, making care possible for others. Now, after being diagnosed with breast cancer, she was the one in need of care.
Why is it that some approved products do not have commercial success and market adoption? There are in my opinion three major reasons; 1) Addressable market based on the product label; 2) Product manufacturability, 3) The pricing power versus the cost. What is at the denominator for all three major reasons for commercial failure?
The root cause is a regulatory strategy that early on fails to define the most critical aspect of product development which is the Target Product Profile (TPP). The TPP is defined in many ways but it essentially involves deciding what the manufacturers have to do clinically to assess the safety and efficacy of their product based on the proposed Mechanism of Action (MOA) and other product attributes. The TPP eventually defines the final drug product label. In reality, what is claimed on the product label is not only a reflection of the product characteristics and MOA but it is also about other factors (see below).
So what should a manufacturer consider in their regulatory strategy to address this root cause? They should consider addressing the four major factors that are directly or indirectly linked to the product TPP; and what is ultimately approved on the final drug product label.
Addressable market based on approved product label: The product label defines the addressable market not vice versa.
Manufacturability: The manufacturers tend to forget that if you cannot make the product consistently at the cost that is affordable to payers, as defined by the labeling claim, the commercial success of a product could be at jeopardy!
Pricing: The pricing power is often determined by the manufacturing cost and what the market can tolerate based on the label of the final drug product and any competing therapies.
The manufacturers often view an optimal regulatory strategy as one that permits them getting access to the market the fastest way but this approach could potentially be short sighted! The real solution to these challenges lies in conducting a careful regulatory strategy analysis, very early on, that encompasses not only the regulatory and technical considerations, but it also includes various considerations as outlined above. For this reason, Parexel has chosen to provide their client’s with an integrated approach for regulatory strategy that considers not only the technology and product attributes, and non-clinical and clinical considerations, but also other factors such as the addressable market based on the final approved labeling, IP considerations, and competing market analysis.
In the end a successful strategy must be commercially sustainable one that requires consideration of some of these aforementioned factors in a sequential manner allowing for commercial, business and marketing assumptions which are based on the best scientific and regulatory analyses.
New Medicines, Novel Insights: Advancing rare disease drug development
May 22, 2023
New Medicines, Novel Insights: Accelerating development of cell and gene therapies
May 22, 2023
The Chinese Pharmaceutical Market: Size, R&D, Regulations, Market Access and Innovations
Mar 9, 2023
Are you using real-world evidence?
Feb 1, 2023
Studying multiple versions of a cellular or gene therapy product in an early-phase clinical trial
Nov 19, 2021
Three strategies for articulating a coherent product value story
Dec 18, 2021
Creating EU-CTR compliant and patient-friendly lay language summaries (LLS)
Jan 26, 2022
New endpoints for early-stage cancer are gaining regulatory traction
Jan 28, 2022
Pragmatic Trials: Targeting evidence generation to inform market access and meet payers’ needs
Feb 8, 2022
EU-CTR: Preparing for trial transition
Nov 30, 2023
On-demand webinar: An expert guide to EU-CTR
Mar 10, 2022
Overview of China's Market Approval Policy Med Insurance Payment System
Apr 7, 2022